Becton Dickinson and Co
NYSE:BDX

Watchlist Manager
Becton Dickinson and Co Logo
Becton Dickinson and Co
NYSE:BDX
Watchlist
Price: 224 USD -0.64% Market Closed
Market Cap: 64.7B USD
Have any thoughts about
Becton Dickinson and Co?
Write Note

Becton Dickinson and Co
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Becton Dickinson and Co
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Becton Dickinson and Co
NYSE:BDX
Free Cash Flow
$3.1B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
11%
Boston Scientific Corp
NYSE:BSX
Free Cash Flow
$2.2B
CAGR 3-Years
12%
CAGR 5-Years
28%
CAGR 10-Years
10%
Edwards Lifesciences Corp
NYSE:EW
Free Cash Flow
$476.8m
CAGR 3-Years
-30%
CAGR 5-Years
-10%
CAGR 10-Years
-7%
Stryker Corp
NYSE:SYK
Free Cash Flow
$3.2B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Free Cash Flow
$5.7B
CAGR 3-Years
-15%
CAGR 5-Years
8%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Free Cash Flow
$586m
CAGR 3-Years
-32%
CAGR 5-Years
-11%
CAGR 10-Years
-1%
No Stocks Found

Becton Dickinson and Co
Glance View

Market Cap
64.7B USD
Industry
Health Care

Becton Dickinson and Co. (BD) is a global leader in the medical technology sector, with a rich history tracing back to its founding in 1897. The company specializes in the development, manufacturing, and distribution of a wide array of medical devices, instrument systems, and reagents that are essential in hospitals and laboratories. BD's products play a pivotal role in improving patient outcomes by enhancing the accuracy of diagnostics and facilitating efficient pharmaceutical delivery. With a commitment to innovation, BD invests significantly in research and development, ensuring it remains at the forefront of advanced technology in healthcare, which resonates well with investors seeking sustainable growth in a resilient industry. The company's diverse portfolio spans three main segments: BD Medical, BD Life Sciences, and BD Biosciences, enabling it to tap into multiple revenue streams while addressing critical healthcare needs worldwide. BD's strategic focus on expanding its presence in emerging markets, coupled with its robust pipeline of new products, positions it favorably for future growth. Additionally, BD’s commitment to operational excellence and cost management bolsters its profitability and shareholder value. For investors, BD offers a compelling opportunity as it navigates the evolving landscape of healthcare, characterized by increasing demand for high-quality medical solutions and a growing emphasis on personalized medicine. As the company continues to deliver innovative products and services while maintaining strong financial fundamentals, it remains a key player to watch in the dynamic world of medical technology.

BDX Intrinsic Value
290.39 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Becton Dickinson and Co's Free Cash Flow?
Free Cash Flow
3.1B USD

Based on the financial report for Sep 30, 2024, Becton Dickinson and Co's Free Cash Flow amounts to 3.1B USD.

What is Becton Dickinson and Co's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
11%

Over the last year, the Free Cash Flow growth was 45%. The average annual Free Cash Flow growth rates for Becton Dickinson and Co have been -4% over the past three years , 5% over the past five years , and 11% over the past ten years .

Back to Top